Berbamine and Stage IV Cancer: Latest Research 2026

By Insight Swarm Research Team, Medical Advisor: Nikhil Joshi, MD, FRCPC

Berbamine and Stage IV Cancer: Latest Research 2026

This page summarizes the current state of scientific research on Berbamine in the context of Stage IV Cancer as of 2026. The field evolves rapidly — this is a research summary, not medical advice. Consult your oncologist for personalized guidance.

Compound Overview

Berbamine (Isoquinoline Alkaloid / Anti-cancer) — Research compound; approved for use in China for leukopenia; not FDA-approved

Mechanism of action: CaMKII inhibitor; calcium channel blocker; induces apoptosis; inhibits NF-κB; anti-proliferative

Current evidence level: Chinese clinical data for leukopenia; anti-cancer data mostly preclinical and Chinese clinical studies

2026 Research Landscape

Research has directly examined Berbamine in Stage IV Cancer, making this a field with active scientific interest.

Key areas researchers are currently examining include:

  • Mechanistic studies: Understanding precisely how Berbamine affects the biological pathways involved in Stage IV Cancer progression
  • Safety characterization: Defining appropriate doses and monitoring protocols if clinical use is considered
  • Biomarker identification: Finding measurable indicators that could predict which patients might respond
  • Clinical trials: Phase I/II investigations examining Berbamine in Stage IV Cancer patients are ongoing or recently completed

Where to Find the Most Current Research

To access the latest peer-reviewed publications:

  • PubMed: Search "(Berbamine[tiab]) AND (Stage IV Cancer[tiab])" at pubmed.ncbi.nlm.nih.gov
  • ClinicalTrials.gov: Search for active and completed trials with Berbamine keywords
  • Google Scholar: Sort by date for most recent publications

Research Gaps

The most significant gaps in the Berbamine + Stage IV Cancer research landscape as of 2026 include: lack of large Phase III randomized trials, limited long-term safety data in Stage IV Cancer patients, and absence of biomarker-selected patient populations who might benefit most.

Medical Disclaimer: This page summarizes published research and is not medical advice. Never start, stop, or change any treatment based on information found online. Always consult qualified healthcare professionals before making treatment decisions.

Get a personalized AI-generated research report at insightswarm.ai.

Frequently Asked Questions

What are the most recent studies on Berbamine for Stage IV Cancer?

The most current peer-reviewed studies can be found on PubMed (pubmed.ncbi.nlm.nih.gov). Search for 'Berbamine Stage IV Cancer' filtered to the last 2 years. The current evidence level is: Chinese clinical data for leukopenia; anti-cancer data mostly preclinical and Chinese clinical studies.

Are there any 2025-2026 clinical trials for Berbamine in Stage IV Cancer?

Check ClinicalTrials.gov with 'Berbamine' as intervention and 'Stage IV Cancer' as condition. Filter by 'Recruiting' status for currently enrolling trials. Your oncologist can advise whether any trials may be appropriate for your specific situation.

Has the evidence for Berbamine in Stage IV Cancer changed recently?

The field evolves rapidly. The current evidence classification is: Chinese clinical data for leukopenia; anti-cancer data mostly preclinical and Chinese clinical studies. For the most up-to-date summary, Insight Swarm generates personalized research reports that incorporate the latest publications specific to your case.